Treatment with bendamustine prior to CAR T-cell therapy in patients with refractory large B-cell lymphoma associates with poorer treatment outcomes, finds a recent study. Led by investigators of the ...

Bendamustine is generally well tolerated. The most common serious (grade 3 or 4) adverse events are hematologic in nature. Gastrointestinal events are also commonly observed but are usually mild to ...

The bendamustine molecule is composed of 3 structural elements: a mechlorethamine (nitrogen mustard) group, a benzimidazole ring, and a butyric acid side chain (Figure 1). The mechlorethamine ...

The Appraisal Committee considered evidence submitted by the manufacturer of bendamustine and a review of this submission by the Evidence Review Group (ERG). One trial was identified by the ...

Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy in Patients With Richter's Syndrome or Fludarabine-Refractory Chronic Lymphocytic Leukemia Seventy-six ...

Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Children’s Oncology Group A total of 245 courses (median, four ...

Bendamustine treatment before apheresis is known to reduce survival in large B-cell lymphoma (LBCL) patients receiving chimeric antigen receptor (CAR) T-cell therapy. Bendamustine has been shown to ...

The appraisal committee considered evidence submitted by Roche, a review of this submission by the evidence review group (ERG), and the technical report developed through engagement with stakeholders.

“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an ...

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when ...